Epigenetic control of autoimmune diseases: From bench to bedside

Clinical Immunology

Volumn 157, Issue 1, 2015, Pages 1-15

  Picascia, Antonietta ^a   Grimaldi, Vincenzo ^a   Pignalosa, Orlando ^a   De Pascale, Maria Rosaria ^a   Schiano, Concetta ^b   Napoli, Claudio ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

Autoimmune disease; DNA methylation; Epigenetic modification; Histone modification; MiRNA

Indexed keywords

DNA METHYLTRANSFERASE 1; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MICRORNA 126; MICRORNA 146A; MICRORNA 155; MICRORNA 223; MICRORNA 26A; MICRORNA 29; MYELIN; HISTONE; RNA;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CHROMATIN STRUCTURE; CPG ISLAND; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE COURSE; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC ASSOCIATION; HISTONE METHYLATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AUTOIMMUNE DISEASES; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; RNA; TWINS, MONOZYGOTIC;

EID: 84921485488     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.12.013     Document Type: Review

References (148)

1. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J. Autoimmun. 2009, 33:3-11.
2. Ballestar E. Epigenetics lessons from twins: prospects for autoimmune disease. Clin. Rev. Allergy Immunol. 2010, 39:30-41.
3. Baranzini S.E. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 2009, 21:596-605.
4. Sollid L.M., Pos W., Wucherpfennig K.W. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr. Opin. Immunol. 2014, 31C:24-30.
5. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. J. Autoimmun. 2012, 39:249-252.
6. Dang M.N., Buzzetti R., Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab. Res. Rev. 2013, 29:8-18.
7. Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmun. Dis. 2014, 2014:437231.
8. Ellis J.A., Kemp A.S., Ponsonby A.L. Gene-environment interaction in autoimmune disease. Exp. Rev. Mol. Med. 2014, 16:e4.
9. Meda F., Folci M., Baccarelli A., Selmi C. The epigenetics of autoimmunity. Cell. Mol. Immunol. 2011, 8:226-236.
10. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
11. Nielsen H.M., Tost J. Epigenetic changes in inflammatory and autoimmune diseases. Subcell. Biochem. 2013, 61:455-478.
12. Mendenhall E.M., Bernstein B.E. Chromatin state maps: new technologies, new insights. Curr. Opin. Genet. Dev. 2008, 18:109-115.
13. Defossez P.A., Stancheva I. Biological functions of methyl-CpG-binding proteins. Prog. Mol. Biol. Transl. Sci. 2011, 101:377-398.
14. Zaratiegui M., Irvine D.V., Martienssen R.A. Noncoding RNAs and gene silencing. Cell 2007, 128:763-776.
15. Ha T.Y. MicroRNAs in human diseases: from autoimmune diseases to skin, psychiatric and neurodegenerative diseases. Immune Netw. 2011, 11:227-244.
16. Denis H., Ndlovu M.N., Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011, 12:647-656.
17. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
18. Moulton V.R., Tsokos G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13:207.
19. Cunninghame Graham D.S. Genome-wide association studies in systemic lupus erythematosus: a perspective. Arthritis Res. Ther. 2009, 11:119.
20. Ballestar E., Esteller M., Richardson B.C. The epigenetic face of systemic lupus erythematosus. J. Immunol. 2006, 176:7143-7147.
21. Zhang Y., Zhao M., Sawalha A.H., Richardson B., Lu Q. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J. Autoimmun. 2013, 41:92-99.
22. Lu Q., Kaplan M., Ray D., Ray D., Zacharek S., Gutsch D., Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 2002, 46:1282-1291.
23. Lu Q., Wu A., Richardson B.C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 2005, 174:6212-6219.
24. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 2007, 179:6352-6358.
25. Zhao M., Sun Y., Gao F., Wu X., Tang J., Yin H., Luo Y., Richardson B., Lu Q. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J. Autoimmun. 2010, 35:58-69.
26. Hedrich C.M., Rauen T., Apostolidis S.A., Grammatikos A.P., Rodriguez Rodriguez N., Ioannidis C., Kyttaris V.C., Crispin J.C., Tsokos G.C. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:13457-13462.
27. Li Y., Zhao M., Yin H., Gao F., Wu X., Luo Y., Zhao S., Zhang X., Su Y., Hu N., Long H., Richardson B., Lu Q. Overexpression of the growth arrest and DNA damage-induced 45alpha gene contributes to autoimmunity by promoting DNA demethylation in lupus T cells. Arthritis Rheum. 2010, 62:1438-1447.
28. Li Y., Huang C., Zhao M., Liang G., Xiao R., Yung S., Chan T.M., Lu Q. A possible role of HMGB1 in DNA demethylation in CD4+ T cells from patients with systemic lupus erythematosus. Clin. Dev. Immunol. 2013, 2013:206298.
29. Coit P., Jeffries M., Altorok N., Dozmorov M.G., Koelsch K.A., Wren J.D., Merrill J.T., McCune W.J., Sawalha A.H. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J. Autoimmun. 2013, 43:78-84.
30. Zhao M., Liu S., Luo S., Wu H., Tang M., Cheng W., Zhang Q., Zhang P., Yu X., Xia Y., Yi N., Gao F., Wang L., Yung S., Chan T.M., Sawalha A.H., Richardson B., Gershwin M.E., Li N., Lu Q. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J. Autoimmun. 2014, 54:127-136.
31. Deng C., Kaplan M.J., Yang J., Ray D., Zhang Z., McCune W.J., Hanash S.M., Richardson B.C. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001, 44:397-407.
32. Gorelik G., Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun. Rev. 2009, 8:196-198.
33. Sunahori K., Nagpal K., Hedrich C.M., Mizui M., Fitzgerald L.M., Tsokos G.C. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J. Biol. Chem. 2013, 288:21936-21944.
34. Pan W., Zhu S., Yuan M., Cui H., Wang L., Luo X., Li J., Zhou H., Tang Y., Shen N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 2010, 184:6773-6781.
35. Rauen T., Hedrich C.M., Juang Y.T., Tenbrock K., Tsokos G.C. cAMP-responsive element modulator (CREM)α protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:43437-43446.
36. Klein K., Gay S. Epigenetic modifications in rheumatoid arthritis, a review. Curr. Opin. Pharmacol. 2013, 13:420-425.
37. Liu C.C., Fang T.J., Ou T.T., Wu C.C., Li R.N., Lin Y.C., Lin C.H., Tsai W.C., Liu H.W., Yen J.H. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol. Lett. 2011, 135:96-99.
38. Lin S.Y., Hsieh S.C., Lin Y.C., Lee C.N., Tsai M.H., Lai L.C., Chuang E.Y., Chen P.C., Hung C.C., Chen L.Y., Hsieh W.S., Niu D.M., Su Y.N., Ho H.N. A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity. Genes Immun. 2012, 13:214-220.
39. Karouzakis E., Rengel Y., Jungel A., Kolling C., Gay R.E., Michel B.A., Tak P.P., Gay S., Neidhart M., Ospelt C. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun. 2011, 12:643-652.
40. Nakano K., Whitaker J.W., Boyle D.L., Wang W., Firestein G.S. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:110-117.
41. Takami N., Osawa K., Miura Y., Komai K., Taniguchi M., Shiraishi M., Sato K., Iguchi T., Shiozawa K., Hashiramoto A., Shiozawa S. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum. 2006, 54:779-787.
42. Nile C.J., Read R.C., Akil M., Duff G.W., Wilson A.G. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 2008, 58:2686-2693.
43. Glossop J.R., Emes R.D., Nixon N.B., Haworth K.E., Packham J.C., Dawes P.T., Fryer A.A., Mattey D.L., Farrell W.E. Genome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated methylation changes that are distinct to individual T- and B-lymphocyte populations. Epigenetics 2014, 9:1228-1237.
44. Kennedy A., Schmidt E.M., Cribbs A.P., Penn H., Amjadi P., Syed K., Read J.E., Green P., Gregory B., Brennan F.M. A novel upstream enhancer of FOXP3, sensitive to methylation-induced silencing, exhibits dysregulated methylation in rheumatoid arthritis Treg cells. Eur. J. Immunol. 2014, 44:2968-2978.
45. Liu Y., Aryee M.J., Padyukov L., Fallin M.D., Hesselberg E., Runarsson A., Reinius L., Acevedo N., Taub M., Ronninger M., Shchetynsky K., Scheynius A., Kere J., Alfredsson L., Klareskog L., Ekström T.J., Feinberg A.P. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 2013, 31:142-147.
46. Küçükali C.I., Kürtüncü M., Coban A., Cebi M., Tüzün E. Epigenetics of multiple sclerosis: an updated review. NeuroMolecular Med. 2014, 10.1007/s12017-014-8298-6.
47. Mastronardi F.G., Noor A., Wood D.D., Paton T., Moscarello M.A. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res. 2007, 85:2006-2016.
48. Huynh J.L., Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol. 2013, 12:195-206.
49. Kumagai C., Kalman B., Middleton F.A., Vyshkina T., Massa P.T. Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects. J. Neuroimmunol. 2012, 246:51-57.
50. Graves M., Benton M., Lea R., Boyle M., Tajouri L., Macartney-Coxson D., Scott R., Lechner-Scott J. Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis. Mult. Scler. 2013, 20:1033-1041.
51. Calabrese R., Zampieri M., Mechelli R., Annibali V., Guastafierro T., Ciccarone F., Coarelli G., Umeton R., Salvetti M., Caiafa P. Methylation-dependent PAD2 upregulation in multiple sclerosis peripheral blood. Mult. Scler. 2012, 18:299-304.
52. Bradford C.M., Ramos I., Cross A.K., Haddock G., McQuaid S., Nicholas A.P., Woodroofe M.N. Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis. J. Neuroimmunol. 2014, 273:85-95.
53. D'Souza C.A., Wood D.D., She Y.M., Moscarello M.A. Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. Biochemistry 2005, 27:12905-12913.
54. Calabrese R., Valentini E., Ciccarone F., Guastafierro T., Bacalini M.G., Ricigliano V.A., Zampieri M., Annibali V., Mechelli R., Franceschi C., Salvetti M., Caiafa P. TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells. Biochim. Biophys. Acta 2014, 1842:1130-1136.
55. Stankov K., Benc D., Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013, 132:1112-1122.
56. Disanto G., Vcelakova J., Pakpoor J., Elangovan R.I., Sumnik Z., Ulmannova T., Ebers G.C., Ramagopalan S.V., Stechová K. DNA methylation in monozygotic quadruplets affected by type 1 diabetes. Diabetologia 2013, 56:2093-2095.
57. Stefan M., Zhang W., Concepcion E., Yi Z., Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J. Autoimmun. 2014, 50:33-37.
58. Rakyan V.K., Beyan H., Down T.A., Hawa M.I., Maslau S., Aden D., Daunay A., Busato F., Mein C.A., Manfras B., Dias K.R., Bell C.G., Tost J., Boehm B.O., Beck S., Leslie R.D. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011, 7:e1002300.
59. Fradin D., Le Fur S., Mille C., Naoui N., Groves C., Zelenika D., McCarthy M.I., Lathrop M., Bougnères P. Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes. PLoS One 2012, 7:e36278.
60. Bell C.G., Teschendorff A.E. V.K. Rakyan, A.P. Maxwell, S. Beck, D.A. Savage, Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med. Genet. 2010, 3:33.
61. Gu T., Falhammar H., Gu H.F., Brismar K. Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in type 1 diabetes and diabetic nephropathy. Clin. Epigenetics 2014, 6:10.
62. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
63. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 2011, 2011:371832.
64. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J. Autoimmun. 2010, 34:J207-J219.
65. Black J.C., Van Rechem C., Whetstine J.R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 2012, 48:491-507.
66. Hu N., Qiu X., Luo Y., Yuan J., Li Y., Lei W., Zhang G., Zhou Y., Su Y., Lu Q. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 2008, 35:804-810.
67. Dai Y., Zhang L., Hu C., Zhang Y. Genome-wide analysis of histone H3 lysine 4 trimethylation by ChIP-chip in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Clin. Exp. Rheumatol. 2010, 28:158-168.
68. Apostolidis S.A., Rauen T., Hedrich C.M., Tsokos G.C., Crispín J.C. Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J. Biol. Chem. 2013, 288:26775-26784.
69. Zhou Y., Qiu X., Luo Y., Yuan J., Li Y., Zhong Q., Zhao M., Lu Q. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus 2011, 20:1365-1371.
70. Zhang Z., Song L., Maurer K., Petri M.A., Sullivan K.E. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 2010, 11:124-133.
71. Regna N.L., Chafin C.B., Hammond S.E., Puthiyaveetil A.G., Caudell D.L., Reilly C.M. Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin. Immunol. 2014, 151:29-42.
72. Viatte S., Plant D., Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:141-153.
73. Huber L.C., Brock M., Hemmatazad H., Giger O.T., Moritz F., Trenkmann M., Distler J.H., Gay R.E., Kolling C., Moch H., Michel B.A., Gay S., Distler O., Jüngel A. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 2007, 56:1087-1093.
74. Gillespie J., Savic S., Wong C., Hempshall A., Inman M., Emery P., Grigg R., McDermott M.F. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum. 2012, 64:418-422.
75. Toussirot E., Wendling D., Herbein G. Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. Joint Bone Spine 2014, 81:544-545. on behalf of CIC-1431.
76. Toussirot E., Abbas W., Khan K.A., Tissot M., Jeudy A., Baud L., Bertolini E., Wendling D., Herbein G. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. PLoS One 2013, 8:e70939.
77. Wada T.T., Araki Y., Sato K., Aizaki Y., Yokota K., Kim Y.T., Oda H., Kurokawa R., Mimura T. Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem. Biophys. Res. Commun. 2014, 444:682-686.
78. Grabiec A.M., Korchynskyi O., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 2012, 71:424-431.
79. Pedre X., Mastronardi F., Bruck W., López-Rodas G., Kuhlmann T., Casaccia P. Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J. Neurosci. 2011, 31:3435-3445.
80. Inkster B., Strijbis E.M., Vounou M., Kappos L., Radue E.W., Matthews P.M., Uitdehaag B.M., Barkhof F., Polman C.H., Montana G., Geurts J.J. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiol. Aging 2013, 34:238-247.
81. Mastronardi F.G., Wood D.D., Mei J., Raijmakers R., Tseveleki V., Dosch H.M., Probert L., Casaccia-Bonnefil P., Moscarello M.A. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 2006, 26:11387-11396.
82. Gray S.G., De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 2005, 21:416-433.
83. Miao F., Wu X., Zhang L., Yuan Y.C., Riggs A.D., Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J. Biol. Chem. 2007, 282:13854-13863.
84. Miao F., Smith D.D., Zhang L., Min A., Feng W., Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008, 57:3189-3198.
85. Yu X.Y., Geng Y.J., Liang J.L., Zhang S., Lei H.P., Zhong S.L., Lin Q.X., Shan Z.X., Lin S.G., Li Y. High levels of glucose induce "metabolic memory" in cardiomyocyte via epigenetic histone H3 lysine 9 methylation. Mol. Biol. Rep. 2012, 39:8891-8898.
86. Miao F., Chen Z., Genuth S., Paterson A., Zhang L., Wu X., Li S.M., Cleary P., Riggs A., Harlan D.M., Lorenzi G., Kolterman O., Sun W., Lachin J.M., Natarajan R., DCCT/EDIC Research Group Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 2014, 63:1748-1762.
87. Brasacchio D., Okabe J., Tikellis C., Balcerczyk A., George P., Baker E.K., Calkin A.C., Brownlee M., Cooper M.E., El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58:1229-1236.
88. Napoli C., Crudele V., Soricelli A., Al-Omran M., Vitale N., Infante T., Mancini F.P. Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms?. Circulation 2012, 125:2363-2373.
89. Napoli C., Infante T., Casamassimi A. Maternal-foetal epigenetic interactions in the beginning of cardiovascular damage. Cardiovasc. Res. 2011, 92:367-374.
90. Cai Y., Yu X., Hu S., Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinform. 2009, 7:147-154.
91. Carlsen A.L., Schetter A.J., Nielsen C.T., Lood C., Knudsen S., Voss A., Harris C.C., Hellmark T., Segelmark M., Jacobsen S., Bengtsson A.A., Heegaard N.H. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 2013, 65:1324-1334.
92. Stagakis E., Bertsias G., Verginis P., Nakou M., Hatziapostolou M., Kritikos H., Iliopoulos D., Boumpas D.T. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann. Rheum. Dis. 2011, 70:1496-1506.
93. Zhao X., Tang Y., Qu B., Cui H., Wang S., Wang L., Luo X., Huang X., Li J., Chen S., Shen N. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 2010, 62:3425-3435.
94. Chan E.K., Satoh M., Pauley K.M. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need?. Arthritis Rheum. 2009, 60:912-915.
95. Tang Y., Luo X., Cui H., Ni X., Yuan M., Guo Y., Huang X., Zhou H., de Vries N., Tak P.P., Chen S., Shen N. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60:1065-1075.
96. Lu L.F., Boldin M.P., Chaudhry A., Lin L.L., Taganov K.D., Hanada T., Yoshimura A., Baltimore D., Rudensky A.Y. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010, 142:914-929.
97. Dai R., Ahmed S.A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl. Res. 2011, 157:163-179.
98. Divekar A.A., Dubey S., Gangalum P.R., Singh R.R. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J. Immunol. 2011, 186:924-930.
99. Miao C.G., Yang Y.Y., He X., Huang C., Huang Y., Zhang L., Lv X.W., Jin Y., Li J. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell. Signal. 2013, 25:1828-1836.
100. Lashine Y.A., Salah S., Aboelenein H.R., Abdelaziz A.I. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 2014, 10.1177/0961203314552117.
101. Chan V.S., Nie Y.J., Shen N., Yan S., Mok M.Y., Lau C.S. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun. Rev. 2012, 12:890-897.
102. Te J.L., Dozmorov I.M., Guthridge J.M., Nguyen K.L., Cavett J.W., Kelly J.A., Bruner G.R., Harley J.B., Ojwang J.O. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010, 5:e10344.
103. Garchow B.G., Bartulos Encinas O., Leung Y.T., Tsao P.Y., Eisenberg R.A., Caricchio R., Obad S., Petri A., Kauppinen S., Kiriakidou M. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol. Med. 2011, 3:605-615.
104. Luo X., Yang W., Ye D.Q., Cui H., Zhang Y., Hirankarn N., Qian X., Tang Y., Lau Y.L., de Vries N., Tak P.P., Tsao B.P., Shen N. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011, 7:e1002128.
105. Li K., Tie H., Hu N., Chen H., Yin X., Peng C., Wan J., Huang W. Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis. Hum. Immunol. 2014, 75:602-608.
106. Stanczyk J., Pedrioli D.M., Brentano F., Sanchez-Pernaute O., Kolling C., Gay R.E., Detmar M., Gay S., Kyburz D. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58:1001-1009.
107. Nakasa T., Miyaki S., Okubo A., Hashimoto M., Nishida K., Ochi M., Asahara H. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008, 58:1284-1292.
108. Spoerl D., Duroux-Richard I., Louis-Plence P., Jorgensen C. The role of miR-155 in regulatory T cells and rheumatoid arthritis. Clin. Immunol. 2013, 148:56-65.
109. Li J., Wan Y., Guo Q., Zou L., Zhang J., Fang Y., Zhang J., Zhang J., Fu X., Liu H., Lu L., Wu Y. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res. Ther. 2010, 12:R81.
110. Pauley K.M., Satoh M., Chan A.L., Bubb M.R., Reeves W.H., Chan E.K. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res. Ther. 2008, 10:R101.
111. Zhou Q., Haupt S., Kreuzer J.T., Hammitzsch A., Proft F., Neumann C., Leipe J., Witt M., Schulze-Koops H., Skapenko A. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2014, 10.1136/annrheumdis-2013-204377.
112. Niimoto T., Nakasa T., Ishikawa M., Okuhara A., Izumi B., Deie M., Suzuki O., Adachi N., Ochi M. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet. Disord. 2010, 11:209.
113. Nakamachi Y., Kawano S., Takenokuchi M., Nishimura K., Sakai Y., Chin T., Saura R., Kurosaka M., Kumagai S. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009, 60:1294-1304.
114. Lu M.C., Yu C.L., Chen H.C., Yu H.C., Huang H.B., Lai N.S. Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. Clin. Exp. Immunol. 2014, 117:641-651.
115. Filková M., Aradi B., Senolt L., Ospelt C., Vettori S., Mann H., Filer A., Raza K., Buckley C.D., Snow M., Vencovský J., Pavelka K., Michel B.A., Gay R.E., Gay S., Jüngel A. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2014, 73:1898-1904.
116. Smigielska-Czepiel K., van den Berg A., Jellema P., van der Lei R.J., Bijzet J., Kluiver J., Boots A.M., Brouwer E., Kroesen B.J. Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes Immun. 2014, 15:115-125.
117. Murata K., Yoshitomi H., Furu M., Ishikawa M., Shibuya H., Ito H., Matsuda S. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheum. 2014, 66:549-559.
118. Ma X., Zhou J., Zhong Y., Jiang L., Mu P., Li Y., Singh N., Nagarkatti M., Nagarkatti P. Expression, regulation and function of microRNAs in multiple sclerosis. Int. J. Med. Sci. 2014, 11:810-818.
119. Soreq H., Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol. Med. 2011, 17:548-555.
120. Du C., Liu C., Kang J., Zhao G., Ye Z., Huang S., Li Z., Wu Z., Pei G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10:1252-1259.
121. Paraboschi E.M., Soldà G., Gemmati D., Orioli E., Zeri G., Benedetti M.D., Salviati A., Barizzone N., Leone M., Duga S., Asselta R. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int. J. Mol. Sci. 2011, 12:8695-8712.
122. Zhang J., Cheng Y., Cui W., Li M., Li B., Guo L. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2014, 266:56-63.
123. Honardoost M.A., Kiani-Esfahani A., Ghaedi K., Etemadifar M., Salehi M. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Gene 2014, 544:28-133.
124. Junker A., Krumbholz M., Eisele S., Mohan H., Augstein F., Bittner R., Lassmann H., Wekerle H., Hohlfeld R., Meinl E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009, 132:3342-3352.
125. Keller A., Leidinger P., Lange J., Borries A., Schroers H., Scheffler M., Lenhof H.P., Ruprecht K., Meese E. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009, 4:e7440.
126. Søndergaard H.B., Hesse D., Krakauer M., Sørensen P.S., Sellebjerg F. Differential microRNA expression in blood in multiple sclerosis. Mult. Scler. 2013, 19:1849-1857.
127. Lindberg R.L., Hoffmann F., Mehling M., Kuhle J., Kappos L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 2010, 40:888-898.
128. Cox M.B., Cairns M.J., Gandhi K.S., Carroll A.P., Moscovis S., Stewart G.J., Broadley S., Scott R.J., Booth D.R., Lechner-Scott J. ANZgene Multiple Sclerosis Genetics Consortium, microRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010, 5:e12132.
129. Sievers C., Meira M., Hoffmann F., Fontoura P., Kappos L., Lindberg R.L. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin. Immunol. 2012, 144:70-79.
130. Miyazaki Y., Li R., Rezk A., Misirliyan H., Moore C., Farooqi N., Solis M., Goiry L.G., de Faria Junior O., Dang V.D., Colman D., Dhaunchak A.S., Antel J., Gommerman J., Prat A., Fillatreau S., Bar-Or A. CIHR/MSSC New Emerging Team Grant in Clinical Autoimmunity and the MSSRF Canadian B cells in MS Team, a novel microRNA-132-Surtuin-1 Axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis. PLoS One 2014, 9:e105421.
131. Haghikia A., Haghikia A., Hellwig K., Baraniskin A., Holzmann A., Décard B.F., Thum T., Gold R. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 2012, 79:2166-2170.
132. Reijerkerk A., Lopez-Ramirez M.A., van Het Hof B., Drexhage J.A., Kamphuis W.W., Kooij G., Vos J.B., van der Pouw Kraan T.C., van Zonneveld A.J., Horrevoets A.J., Prat A., Romero I.A., de Vries H.E. MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. J. Neurosci. 2013, 33:6857-6863.
133. Chen H., Lan H.Y., Roukos D.H., Cho W.C. Application of microRNAs in diabetes mellitus. J. Endocrinol. 2014, 222:R1-R10.
134. Yang M., Ye L., Wang B., Gao J., Liu R., Hong J., Wang W., Gu W., Ning G. Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients. J. Diabetes 2014, 10.1111/1753-0407.12163.
135. Sebastiani G., Grieco F.A., Spagnuolo I., Galler L., Cataldo D., Dotta F F. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab. Res. Rev. 2011, 27:862-866.
136. Salas-Pérez F., Codner E., Valencia E., Pizarro C., Carrasco E., Pérez-Bravo F. MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology 2013, 218:733-737.
137. Ruan Q., Wang T., Kameswaran V., Wei Q., Johnson D.S., Matschinsky F., Shi W., Chen Y.H. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12030-12035.
138. Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010, 260:70-74.
139. Alvarez M.L., Distefano J.K. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Res. Clin. Pract. 2013, 99:1-11.
140. New M., Olzscha H., La Thangue N.B. HDAC inhibitor-based therapies: can we interpret the code?. Mol. Oncol. 2012, 6:637-656.
141. Azad N., Zahnow C.A., Rudin C.M., Baylin S.B. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10:256-266.
142. Reilly C.M., Regna N., Mishra N. HDAC inhibition in lupus models. Mol. Med. 2011, 17:417-425.
143. Vojinovic J., Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol. Med. 2011, 17:397-403.
144. Hsieh I.N., Liou J.P., Lee H.Y., Lai M.J., Li Y.H., Yang C.R. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell. Death Dis. 2014, 5:e1166.
145. Vojinovic J., Damjanov N., D'Urzo C., Furlan A., Susic G., Pasic S., Iagaru N., Stefan M., Dinarello C.A. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011, 63:1452-1458.
146. Wang G., Tam L.S., Li E.K., Kwan B.C., Chow K.M., Luk C.C., Li P.K., Szeto C.C. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J. Rheumatol. 2010, 37:2516-2522.
147. Meaburn E., Schulz R. Next generation sequencing in epigenetics: insights and challenges. Semin. Cell Dev. Biol. 2012, 23:192-199.
148. Zullo A., Casamassimi A., Mancini F.P., Napoli C. Cardiovascular disease and transgenerational epigenetic effects. Transgenerational Epigenetics 2014, 321-341. Elsevier Inc., San Diego. T. Tollefsbol (Ed.).